Membrane-Anchored and Tumor-Targeted IL12 (attIL12)-PBMC Therapy for Osteosarcoma

Area of Science:

• Oncology
• Immunotherapy
• Cell Therapy

Background:

• Chimeric antigen receptor (CAR) T-cell therapy shows promise for hematologic cancers but faces challenges in solid tumor treatment, including lengthy T-cell expansion and severe toxicity.
• Current CAR T-cell approaches are limited in efficacy and applicability for solid tumors like osteosarcoma.

Purpose of the Study:

• To develop an alternative immunotherapy for solid tumors that overcomes the limitations of CAR T-cell therapy.
• To create a cell-based therapy that avoids the need for extensive T-cell expansion and reduces toxicity.

Main Methods:

• Generation of a cell membrane-anchored, tumor-targeted interleukin-12 (attIL12) to modify peripheral blood mononuclear cells (PBMC).
• Administration of attIL12-PBMC therapy to patient-derived xenograft and metastatic osteosarcoma models.
• Evaluation of therapeutic efficacy, toxicity, and underlying mechanisms, including cytokine release and cellular differentiation.

Main Results:

• AttIL12-PBMC therapy demonstrated significant antitumor efficacy in both heterogeneous osteosarcoma patient-derived xenograft and metastatic osteosarcoma models.
• The treatment exhibited no observable toxic effects.
• Mechanisms included tumor-restricted antitumor cytokine release, attIL12-PBMC accumulation within tumors, and induction of osteosarcoma cell differentiation into bone-like cells, inhibiting tumor growth.

Conclusions:

• AttIL12-PBMC therapy presents a safe and effective treatment strategy for osteosarcoma.
• The simplified production process of attIL12-PBMC enhances feasibility for clinical translation.
• This approach holds potential for broader application in solid tumor treatment, moving towards clinical trials.